PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-202113	(2S,4R)-1-((S)-14-((4-((2-Amino-5-(thiophen-2-yl)phenyl)carbamoyl)phenyl)amino)-2-(tert-butyl)-4,14-dioxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	2669785-80-0	VHL	HDAC1 HDAC2 HDAC3	Inquiry
Molecular Weight: 926.13 Molecular Formula: C47H55N7O9S2 Boiling Point: 1089.4±65.0°C at 760 Torr Density: 1.335±0.06 g/cm3 Description: It is a class I histone deacetylase PROTAC that degrades HDAC1/2 and is essential for inducing apoptosis and cell arrest in cancer cells.
	BPL-202114	JPS035	2669785-84-4	VHL	HDAC1 HDAC3 HDAC2	Inquiry
Molecular Weight: 896.17 Molecular Formula: C49H65N7O7S Boiling Point: 1049.0±65.0°C at 760 Torr Density: 1.234±0.06 g/cm3 Description: It is a class I histone deacetylase PROTAC that degrades HDAC1/2 and is essential for inducing apoptosis and cell arrest in cancer cells.
	BPL-202115	JPS036	2669785-85-5	VHL	HDAC3 HDAC1 HDAC2	Inquiry
Molecular Weight: 940.19 Molecular Formula: C51H66FN7O7S Boiling Point: 1064.9±65.0°C at 760 Torr Density: 1.29±0.1 g/cm3 Description: It is a class I histone deacetylase PROTAC that degrades HDAC1/2 and is essential for inducing apoptosis and cell arrest in cancer cells.
	BPL-202116	N1-(4-(2-(((2S,4R)-1-((S)-2-Acetamido-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)butyl)-N6-(4-((2-aminophenyl)carbamoyl)phenyl)adipamide		VHL	HDAC1 HDAC2 HDAC3	Inquiry
Molecular Weight: 897.11 Molecular Formula: C47H60N8O8S Description: It is a class I histone deacetylase PROTAC that degrades HDAC1/2 and is essential for inducing apoptosis and cell arrest in cancer cells.
	BPL-202117	N1-(4-(2-(((2S,4R)-1-((S)-2-Acetamido-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)butyl)-N9-(4-((2-aminophenyl)carbamoyl)phenyl)nonanediamide		VHL	HDAC1 HDAC2 HDAC3	Inquiry
Molecular Weight: 939.19 Molecular Formula: C50H66N8O8S Description: It is a class I histone deacetylase PROTAC that degrades HDAC1/2 and is essential for inducing apoptosis and cell arrest in cancer cells.
	BPL-202118	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-N4'-(4-((2-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-51-0	CRBN	EZH2	Inquiry
Molecular Weight: 844.97 Molecular Formula: C47H52N6O9 Boiling Point: 1070.3±65.0°C at 760 Torr Density: 1.308±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202119	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-N4'-(2-(2-((2-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-54-3	CRBN	EZH2	Inquiry
Molecular Weight: 860.97 Molecular Formula: C47H52N6O10 Boiling Point: 1079.0±65.0°C at 760 Torr Density: 1.319±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202120	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-N4'-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-55-4	CRBN	EZH2	Inquiry
Molecular Weight: 905.02 Molecular Formula: C49H56N6O11 Boiling Point: 1097.7±65.0°C at 760 Torr Density: 1.290±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202121	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-N4'-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)hexyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-56-5	CRBN	EZH2	Inquiry
Molecular Weight: 930.07 Molecular Formula: C51H59N7O10 Boiling Point: 1160.7±65.0°C at 760 Torr Density: 1.278±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202122	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-N4'-(8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)octyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-57-6	CRBN	EZH2	Inquiry
Molecular Weight: 958.13 Molecular Formula: C53H63N7O10 Boiling Point: 1166.4±65.0°C at 760 Torr Density: 1.259±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202123	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-N4'-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-58-7	CRBN	EZH2	Inquiry
Molecular Weight: 949.07 Molecular Formula: C51H60N6O12 Boiling Point: 1116.1±65.0°C at 760 Torr Density: 1.281±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202124	(2S,4R)-1-((S)-2-(2-(2-((3'-(((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-5'-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4'-methyl-[1,1'-biphenyl]-4-yl)oxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	2230914-75-5	VHL	EZH2	Inquiry
Molecular Weight: 1004.26 Molecular Formula: C55H69N7O9S Boiling Point: 1169.0±65.0°C at 760 Torr Density: 1.237±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202125	YM281	2230914-84-6	VHL	EZH2	Inquiry
Molecular Weight: 1018.29 Molecular Formula: C56H71N7O9S Boiling Point: 1169.3±65.0°C at 760 Torr Density: 1.229±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202126	YM181	2230914-74-4	VHL	EZH2	Inquiry
Molecular Weight: 1048.32 Molecular Formula: C57H73N7O10S Boiling Point: 1186.8±65.0°C at 760 Torr Density: 1.231±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202127	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-N4'-(2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-45-2	VHL	EZH2	Inquiry
Molecular Weight: 1075.34 Molecular Formula: C58H74N8O10S Boiling Point: 1228.5±65.0°C at 760 Torr Density: 1.239±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202128	(2S,4R)-1-((S)-2-(tert-Butyl)-14-((3'-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-5'-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4'-methyl-[1,1'-biphenyl]-4-yl)oxy)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	2230914-58-4	VHL	EZH2	Inquiry
Molecular Weight: 1092.37 Molecular Formula: C59H77N7O11S Boiling Point: 1204.7±65.0°C at 760 Torr Density: 1.226±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202129	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-N4'-((S)-14-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-15,15-dimethyl-12-oxo-3,6,9-trioxa-13-azahexadecyl)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-47-4	VHL	EZH2	Inquiry
Molecular Weight: 1133.42 Molecular Formula: C61H80N8O11S Boiling Point: 1253.4±65.0°C at 760 Torr Density: 1.227±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202130	N3-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-N4'-((S)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-18,18-dimethyl-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)-4-methyl-[1,1'-biphenyl]-3,4'-dicarboxamide	2685873-48-5	VHL	EZH2	Inquiry
Molecular Weight: 1177.48 Molecular Formula: C63H84N8O12S Boiling Point: 1270.2±65.0°C at 760 Torr Density: 1.223±0.06 g/cm3 Description: It is a VHL-based EZH2 degrader that enhances the therapeutic activity against lymphoma.
	BPL-202131	N-(2-(2-((6-((7-(Benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5-yl)amino)hexyl)amino)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide		CRBN	CDK9	Inquiry
Molecular Weight: 781.92 Molecular Formula: C41H51N9O7 Description: It is a potent and selective CDK9 degrader for targeting transcription regulation in triple-negative breast cancer.
	BPL-202132	N-(18-((7-(Benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5-yl)amino)-3,6,9-trioxa-12-azaoctadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide		CRBN	CDK9	Inquiry
Molecular Weight: 870.02 Molecular Formula: C45H59N9O9 Description: It is a potent and selective CDK9 degrader for targeting transcription regulation in triple-negative breast cancer.